Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Cerep Partner on Drug Discovery Tools

NEW YORK (GenomeWeb News) – PerkinElmer today announced that it has signed a co-marketing agreement with Cerep to provide custom drug discovery tools and services to customers.
 
Under the agreement, PerkinElmer will exclusively market Cerep’s target screening and profiling services to its customers. The firms also will jointly promote PerkinElmer’s assay technologies and Cerep’s high-throughput screening and profiling services to the drug discovery market.
 
PerkinElmer said that the alliance provides its customers with an option to work with a single vendor throughout the entire drug discovery process.
 
“This agreement represents the latest step in our strategy to build the most comprehensive offering in biochemical and cellular screening for drug discovery,” PerkinElmer President and CEO Robert Friel said in a statement.
 
The firm rapidly expanded its cellular analysis and screening business early in 2007 with the acquisitions of Evotec Technologies, Euroscreen Products, and Improvision.
 
Paris-based Cerep specializes in custom binding, cellular, and tissue assay services. It also has developed the BioPrint pharmacoinformatics platform.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.